HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

20 Aug 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

31 Jul 2023 06:41:53 By Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

19 Jul 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

13 Jul 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

09 Jul 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Half-Year Financial Results

26 Jun 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

15 Jun 2023 19:30:00 By Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

15 Jun 2023 09:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 Jun 2023 04:30:00 By Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

25 May 2023 18:00:54 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

25 May 2023 17:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Board of Directors and Board Committee Membership

12 May 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

10 May 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

17 Apr 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

11 Apr 2023 19:00:00 By Nasdaq GlobeNewswire

Intended Retirement of Independent Non-executive Director

11 Apr 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

04 Apr 2023 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

30 Mar 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

14 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

12 Mar 2023 19:07:31 By Nasdaq GlobeNewswire